Reports Q2 revenue $104.6M, consensus $104.08M. “Our commercial team has continued to field significant interest from customers seeking to expand their use of model-informed drug development,” said William Feehery, CEO. “We are excited about software product enhancements and new product introductions that will expand our market leading offering and deliver sustainable long-term growth.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara announces EMA qualification of Simcyp Simulator
- Certara appoints Christopher Bouton as CTO
- Certara expands clinical technology collaboration with Merck
- Certara assumed with an Equal Weight at Morgan Stanley
- Certara’s Steady Growth Amid Strategic and Regulatory Uncertainties: A Hold Rating Analysis